Compare PIPR & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PIPR | KYMR |
|---|---|---|
| Founded | 1895 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.4B |
| IPO Year | N/A | 2020 |
| Metric | PIPR | KYMR |
|---|---|---|
| Price | $339.13 | $78.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 23 |
| Target Price | ★ $362.50 | $105.35 |
| AVG Volume (30 Days) | 126.2K | ★ 1.5M |
| Earning Date | 01-30-2026 | 11-04-2025 |
| Dividend Yield | ★ 1.71% | N/A |
| EPS Growth | ★ 42.49 | N/A |
| EPS | ★ 13.30 | N/A |
| Revenue | ★ $1,717,433,000.00 | $43,735,000.00 |
| Revenue This Year | $17.11 | $18.71 |
| Revenue Next Year | $15.11 | N/A |
| P/E Ratio | $25.55 | ★ N/A |
| Revenue Growth | ★ 13.46 | N/A |
| 52 Week Low | $202.91 | $19.45 |
| 52 Week High | $374.77 | $103.00 |
| Indicator | PIPR | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 45.73 | 51.31 |
| Support Level | $346.02 | $77.28 |
| Resistance Level | $355.55 | $85.41 |
| Average True Range (ATR) | 8.57 | 3.47 |
| MACD | -1.57 | -1.40 |
| Stochastic Oscillator | 7.82 | 7.35 |
Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services followed by Equity financing.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.